Actively Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
Led by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Updated on 2025-12-18
194
Participants Needed
32
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.
CONDITIONS
Official Title
Clinical Studies for the Treatment of Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be at least 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
- Have at least one measurable tumor lesion by RECIST v1.1
- All acute toxicities from prior cancer treatments have resolved to Grade 0-1 or are not safety risks
- Have adequate organ and bone marrow function as defined by specific blood counts, liver and kidney tests, coagulation, urine protein, and cardiac function
- Expected survival of at least 12 weeks
- Non-childbearing women or agreement to use approved contraception and negative pregnancy test if childbearing potential
- Able and willing to comply with study visits, treatments, and procedures
- For Cohorts A1 and A2: confirmed gastric or gastroesophageal junction cancer, HER2 negative, no prior systemic therapy for advanced disease, and provide tumor tissue samples
- For Cohorts A3 and A4: confirmed advanced or metastatic solid tumors and failed at least one prior standard therapy
You will not qualify if you...
- Known Microsatellite Instability-High (MSI-H) or deficient mismatch repair (dMMR)
- Uncontrolled or symptomatic active central nervous system metastases
- Uncontrolled pleural effusion, ascites, or symptomatic pericardial effusion
- Weight loss greater than 20% in the past 2 months
- Prior treatment with CCR8 antibody, CTLA-4 antibody, or other drugs targeting regulatory T cells before enrollment
- Major surgery within 28 days prior to enrollment except diagnostic procedures
- Use of immunosuppressive medications within 14 days prior to enrollment except low-dose steroids or nasal/inhaled corticosteroids
- Live attenuated vaccine within 28 days before enrollment or planned during study and 60 days after treatment
- Anti-tumor therapy within 28 days prior to enrollment
- Diagnosis of another malignancy within 5 years except certain treated skin and other specific cancers
- Active or suspected autoimmune disease requiring systemic immunosuppression
- Significant bleeding or thrombotic events within past 3 to 6 months
- Severe wounds, ulcers, fractures, or grade >1 peripheral neuropathy
- Recent gastrointestinal perforation, fistula, obstruction unless resolved by surgery
- Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases
- Known allergy to study drugs or other monoclonal antibodies
- HIV infection, untreated active hepatitis B or C, or co-infection
- Uncontrolled cardiac diseases or recent myocardial infarction
- Recent systemic antibiotic use for 7 or more days or unexplained fever >38.5°C
- History of allogeneic organ or stem cell transplantation
- Participation in other drug trials within 4 weeks or 5 half-lives of last drug
- History of psychotropic substance or drug abuse
- Other serious physical or psychiatric illnesses or laboratory abnormalities that increase risk or interfere with study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 32 locations
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230031
Not Yet Recruiting
2
The Second Hospital of Anhui Medical University
Hefei, Anhui, China, 230601230601
Not Yet Recruiting
3
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
4
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Not Yet Recruiting
5
The First Hospital of Lanzhou University
Lanzhou, Gansu, China, 730030
Not Yet Recruiting
6
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China, 733099
Not Yet Recruiting
7
Peking University Shenzhen Hospita
Shenzhen, Guangdong, China, 518000
Not Yet Recruiting
8
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Not Yet Recruiting
9
Tangshan People's Hospital
Tangshan, Hebei, China, 063001
Not Yet Recruiting
10
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150040
Not Yet Recruiting
11
Nanyang Second General Hospital
Nanyang, Henan, China, 473012
Not Yet Recruiting
12
Ping mei shen ma Medical Group General Hospital
Pingdingshan, Henan, China, 467000
Actively Recruiting
13
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450002
Not Yet Recruiting
14
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Not Yet Recruiting
15
The second xiangya hospital of central south university
Changsha, Hunan, China, 410011
Not Yet Recruiting
16
Inner Mongolia Hospital of Peking University Cancer Hospita
Hohhot, Inner Mongolia, China, 010000
Not Yet Recruiting
17
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China, 210000
Not Yet Recruiting
18
NanJing Drum Tower Hospital
Nanjing, Jiangsu, China, 210000
Not Yet Recruiting
19
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Not Yet Recruiting
20
XuZhou Central Hospital
Xuzhou, Jiangsu, China, 221000
Not Yet Recruiting
21
Jilin Cancer Hospital
Changchun, Jilin, China, 130000
Not Yet Recruiting
22
The First Hospital Of China Medical University
Shenyang, Liaoning, China, 110000
Not Yet Recruiting
23
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, Shaanxi, China, 710000
Not Yet Recruiting
24
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China, 264000
Not Yet Recruiting
25
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Not Yet Recruiting
26
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200120
Not Yet Recruiting
27
First Hospital of Shangxi Medical University
Taiyuan, Shangxi, China, 030001
Not Yet Recruiting
28
Shanxi Cancer Hospital
Taiyuan, Shanxi, China, 030000
Not Yet Recruiting
29
Sichuan Cancer Hospita
Chengdu, Sichuan, China, 610042
Not Yet Recruiting
30
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300000
Not Yet Recruiting
31
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, Xinjiang, China, 830054
Not Yet Recruiting
32
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China, 325005
Not Yet Recruiting
Research Team
L
Lin Shen, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here